Skip to main content
. 2024 Aug 26;13(1):2388315. doi: 10.1080/2162402X.2024.2388315

Figure 2.

Figure 2.

Bar graph for patients who experienced an objective response. Light yellow bars are for cemiplimab beyond-progression. Grey bars are for best supportive care (BSC).